|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in aduhs with refractory and relapsed acute leukemias 显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，7： | 1 |
| 2 | Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia显示文摘 | Gore SD Gojo I Sekeres MA | 2010 | J Clin Oncol2010，28，6： | 1 |
| 3 | Phase I study of the heat shock protein 90 inhibitor alvespimycin ( KOS-1022, 17-DMAG) administered intravenously twice weekly to pa- tients with acute myeloid leukemia显示文摘 | Lancet JE Gojo I Burton M | 2010 | Leukemia2010，24，： | 1 |
| 4 | Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-beta-d- arabinofuranosylcytosine, mitoxantrone, and bevacizumab 显示文摘 | Karp J E Gojo I Pili R | 2004 | Clin Cancer Res2004，10，11： | 1 |
| 5 | Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia显示文摘 | Evans MW Sung AD Gojo I | 2012 | Leuk Lymphoma2012，53，4： | 1 |
| 6 | Aphase Ⅱ study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60:two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poorrisk AML显示文摘 | BOLANOS-MEADE J GUO C GOJO I | 2004 | Leuk Res2004，28，： | 1 |
| 7 | Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias:therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab 显示文摘 | Karp JE Gojo I Pili R | 2004 | Clin Cancer Res2004，10，11： | 1 |
| 8 | Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias:therapy with sequential 1-beta-d-arabino -furanosylcytosine,mitoxantrone,and bevacizumab显示文摘 | KARP J E GOJO I PILI R | 2004 | Clin Cancer Res2004，10，11： | 1 |
| 9 | New treatment approaches in acute myeloid leukemia: review of recent clinical studies 显示文摘 | Norsworthy K Luznik L Gojo I | 2012 | Rev Recent Clin Trials2012，7，3： | 1 |
| 10 | The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down regulation of Mcl-1显示文摘 | Gojo I Zhang B Fenton RG | 2002 | Clin Cancer Res2002，8，8： | 1 |
| 11 | Single cycle of arsenic ttrioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia 显示文摘 | Gore SD Gojo I Sekeres MA | 2010 | J Clin Oncol2010，28，6： | 1 |
| 12 | A phase 2 study of the famesyl- transferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia 显示文摘 | Lancet JE Gojo I Gotlib J | 2007 | Blood2007，109，4： | 1 |
| 13 | New treatment approaches in acute myeloid leukemia:review of recent clinical studies显示文摘 | Norsworthy K Luznik L Gojo I | | 0，，： | 1 |
| 14 | High-dose cyclophospha- mide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple rnyeloma: efficacy and toxicity 显示文摘 | Gojo I Guo C Sarkodee-Adoo C | 2004 | Bone Marrow Transplant2004，34，1： | 1 |
| 15 | Single cycle of arsenic ttrioxide- based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia 显示文摘 | Gore SD Gojo I Sekeres MA | 2010 | J Clin Oncol2010，28，： | 1 |
| 16 | Phase 1 and pharmacologic study of MS-275,a histone deacetylase inhibitor,in adults with refractory and relapsed acute leukemias显示文摘 | Gojo I Jiemjit A Trepel J B | 2007 | Blood2007，109，7： | 1 |
| 17 | Myeloid cell factor-1 is a critical survival factor for multiple myeloma显示文摘 | Zhang B Gojo I Fenton R G | | 0，，06： | 1 |
| 18 | Myeliod cell factor-1 is a critical survival factor for multiple myeloma 显示文摘 | Zhang B Gojo I Fenton RG | 2002 | Blood2002，99，6： | 1 |
| 19 | Myeloid cell factor-1 is a critical survival factor for multiple myeloma显示文摘 | Zhang B Gojo I Fenton RG | 2002 | Blood2002，99，6： | 1 |
| 20 | Phase 1 and pharmacologic study of MS-275,a histone deacetylase inhibitor,in adults with refractory and relapsed acute leukemias显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员